Skip to main content
main-content

01.01.2012 | Original Article | Ausgabe 1/2012

European Journal of Nuclear Medicine and Molecular Imaging 1/2012

Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer

Zeitschrift:
European Journal of Nuclear Medicine and Molecular Imaging > Ausgabe 1/2012
Autoren:
Shengri Liao, Bill C. Penney, Kristen Wroblewski, Hao Zhang, Cassie A. Simon, Rony Kampalath, Ming-Chi Shih, Naoko Shimada, Sheng Chen, Ravi Salgia, Daniel E. Appelbaum, Kenji Suzuki, Chin-Tu Chen, Yonglin Pu

Abstract

Purpose

The objective of this study was to assess the prognostic value of metabolic tumor burden on 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) positron emission tomography (PET)/CT measured with metabolic tumor volume (MTV) and total lesion glycolysis (TLG), independent of Union Internationale Contra la Cancrum (UICC)/American Joint Committee on Cancer (AJCC) tumor, node, and metastasis (TNM) stage, in comparison with that of standardized uptake value (SUV) in nonsurgical patients with non-small cell lung cancer (NSCLC).

Methods

This study retrospectively reviewed 169 consecutive nonsurgical patients (78 men, 91 women, median age of 68 years) with newly diagnosed NSCLC who had pretreatment 18F-FDG PET/CT scans. The 18F-FDG PET/CT scans were performed in accordance with National Cancer Institute guidelines. The MTV of whole-body tumor (MTVWB), of primary tumor (MTVT), of nodal metastases (MTVN), and of distant metastases (MTVM); the TLG of whole-body tumor (TLGWB), of primary tumor (TLGT), of nodal metastases (TLGN), and of distant metastases (TLGM); the SUVmax of whole-body tumor (SUVmaxWB), of primary tumor (SUVmaxT), of nodal metastases (SUVmaxN), and of distant metastases (SUVmaxM) as well as the SUVmean of whole-body tumor (SUVmeanWB), of primary tumor (SUVmeanT), of nodal metastases (SUVmeanN), and of distant metastases (SUVmeanM) were measured with the PETedge tool on a MIMvista workstation with manual adjustment. The median follow-up among survivors was 35 months from the PET/CT (range 2–82 months). Statistical methods included Kaplan-Meier curves, Cox regression, and C-statistics.

Results

There were a total of 139 deaths during follow-up. Median overall survival (OS) was 10.9 months [95% confidence interval (CI) 9.0–13.2 months]. The MTV was statistically associated with OS. The hazard ratios (HR) for 1 unit increase of ln(MTVWB), √(MTVT), √(MTVN), and √(MTVM) before/after adjusting for stage were: 1.47/1.43 (p < 0.001/<0.001), 1.06/1.05 (p < 0.001/<0.001), 1.11/1.10 (p < 0.001/<0.001), and 1.04/1.03 (p = 0.007/0.043), respectively. TLG had statistically significant associations with OS with the HRs for 1 unit increase in ln(TLGWB), √(TLGT), √(TLGN), and √(TLGM) before/after adjusting for stage being 1.36/1.33 (p < 0.001/<0.001), 1.02/1.02 (p = 0.001/0.002), 1.05/1.04 (p < 0.001/<0.001), and 1.02/1.02 (p = 0.003/0.024), respectively. The ln(SUVmaxWB) and √(SUVmaxN) were statistically associated with OS with the corresponding HRs for a 1 unit increase before/after adjusting for stage being 1.46/1.43 (p = 0.013/0.024) and 1.22/1.16 (p = 0.002/0.040). The √(SUVmeanN) was statistically associated with OS before and after adjusting for stage with HRs for a 1 unit increase of 1.32 (p < 0.001) and 1.24 (p = 0.015), respectively. The √(SUVmeanM) and √(SUVmaxM) were statistically associated with OS before adjusting for stage with HRs for a 1 unit increase of 1.26 (p = 0.017) and 1.18 (p = 0.007), respectively, but not after adjusting for stage (p = 0.127 and 0.056). There was no statistically significant association between OS and √(SUVmaxT), ln(SUVmeanWB), or √(SUVmeanT). There was low interobserver variability among three radiologists with intraclass correlation coefficients (ICC) greater than 0.94 for SUVmaxWB, ln(MTVWB), and ln(TLGWB). Interobserver variability was higher for SUVmeanWB with an ICC of 0.806.

Conclusion

Baseline metabolic tumor burdens at the level of whole-body tumor, primary tumor, nodal metastasis, and distant metastasis as measured with MTV and TLG on FDG PET are prognostic measures independent of clinical stage with low inter-observer variability and may be used to further stratify nonsurgical patients with NSCLC. This study also suggests MTV and TLG are better prognostic measures than SUVmax and SUVmean. These results will need to be validated in larger cohorts in a prospective study.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt e.Med zum Sonderpreis bestellen!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

European Journal of Nuclear Medicine and Molecular Imaging 1/2012 Zur Ausgabe
  1. Sie können e.Med Radiologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.